| 1. |
|
|
| 2. |
- Kahkonen, Henri, et al.
(författare)
-
Comparison of additively manufactured and machined antenna array performance at Ka band
- 2022
-
Ingår i: IEEE Antennas and Wireless Propagation Letters. - : Institute of Electrical and Electronics Engineers Inc.. - 1536-1225 .- 1548-5757. ; 21:1, s. 9-13
-
Tidskriftsartikel (refereegranskat)abstract
- Additive manufacturing (AM) is a rapidly developing field which potentially decreases the manufacturing costs and enables increasingly complex antenna shapes. Metal-based AM might be particularly useful to manufacture antennas at mm-wave range, because there antennas are physically small enough making additive manufacturing cost efficient, and manufacturing accuracy could still suffice for good electrical performance. In this paper, two additively manufactured and an identical machined fully metallic Ka-band Vivaldi antenna arrays are compared. The manufactured antenna arrays are compared using RF-measurements to conclude the feasibility of AM for manufacturing antenna arrays at mm-wave frequencies. Comparison of the measured radiation patterns and realized gains of each of the antenna arrays between 26 and 40 GHz shows close to identical radiation patterns for all the arrays. A loss in efficiency of 0.51.5 dB is observed in the AM arrays when compared to the machined array due to the used materials and the surface roughness.
|
|
| 3. |
- Palazzo, Leonardo, et al.
(författare)
-
Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus : results from five phase III trials of belimumab
- 2024
-
Ingår i: Rheumatology. - : Oxford University Press. - 1462-0324 .- 1462-0332. ; 63:3, s. 798-808
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVE: To identify determinants of neuropsychiatric (NP) flares in patients with systemic lupus erythematosus (SLE) treated for active SLE yet no ongoing severe NPSLE with non-biologic standard therapy plus belimumab or placebo.METHODS: We analysed data from five phase III trials (BLISS-52, BLISS-76, BLISS-NEA, BLISS-SC, EMBRACE; N = 3638) after exclusion of patients with baseline NP BILAG A. Factors associated with NPSLE flare, defined as a new NP BILAG A or B, were investigated using Cox regression. In a subgroup analysis, we studied patients with baseline NP BILAG E for determinants of de novo NPSLE flare. Organ damage was assessed using the SLICC/ACR Damage Index (SDI). RESULTS: We documented 105 (2.9%) NPSLE flares. In multivariable analysis, male sex (HR = 2.37; 95% CI: 1.31-4.28; p = 0.004), baseline NP BILAG B-D (HR = 5.91; 95% CI: 3.86-9.06; p < 0.001), and increasing SDI scores (HR = 1.35; 95% CI: 1.21-1.50; p < 0.001) were strongly associated with NPSLE flare. Belimumab use yielded no association at any dose or administration form. In analysis of SDI domains, NP damage was the strongest determinant of NPSLE flare (HR = 3.25; 95% CI: 2.72-3.88; p < 0.001), holding true for cognitive impairment (HR = 14.29; 95% CI: 9.22-22.14; p < 0.001), transverse myelitis (HR = 21.89; 95% CI: 5.40-88.72; p < 0.001), and neuropathy (HR = 8.87; 95% CI: 5.59-14.09; p < 0.001). Male sex was the strongest determinant of de novo NPSLE flare (HR = 3.26; 95% CI: 1.51-7.04; p = 0.003).CONCLUSION: Male sex, NPSLE history, and NP damage were strong determinants of impending NPSLE flare. No clear protection or predisposition was conferred from add-on belimumab.
|
|
| 4. |
- Parodis, Ioannis, 1981-, et al.
(författare)
-
Effect of Belimumab on Preventing de novo Renal Lupus Flares
- 2023
-
Ingår i: Kidney international reports. - : Elsevier. - 2468-0249. ; 8:9, s. 1822-1830
-
Tidskriftsartikel (refereegranskat)abstract
- INTRODUCTION: Belimumab was recently approved for treating lupus nephritis (LN), yet de novo LN cases during belimumab treatment given for nonrenal causes have been reported. Identification of reliable signals of impending flare is imperative.METHODS: We evaluated belimumab efficacy in preventing de novo renal flares and factors associated with renal flare occurrence in nephritis-naïve patients with systemic lupus erythematosus (SLE) who are receiving add-on belimumab or placebo in 5 phase 3 clinical trials using Cox regression analysis.RESULTS: Of 1844 eligible patients, 136 (7.4%) developed a de novo renal flare during a 52-week long follow-up. Asian origin (Adjusted Hazard Ratio [HRadj]: 1.97; 95% confidence interval [CI]: 1.32-2.94; P = 0.001), positive baseline anti-double stranded DNA (anti-dsDNA) levels (HRadj: 1.32; 95% CI: 1.07-1.63; P = 0.008), and increasing mean prednisone dose during follow-up (HRadj: 1.03; 95% CI: 1.02-1.04; P < 0.001) were associated with de novo renal flares. Low-dose intravenous (IV) belimumab (1 mg/kg monthly) yielded a nearly 3-fold lower hazard of de novo renal flare (HRadj: 0.38; 95% CI: 0.20-0.73; P = 0.004). Subcutaneous (SC) belimumab (200 mg weekly) also yielded a lower hazard (HRadj.: 0.69; 95% CI: 0.54-0.88; P = 0.003). The labeled IV dose (10 mg/kg monthly) conferred no clear protection (HRadj.: 0.74; 95% CI: 0.50-1.09; P = 0.127).CONCLUSION: We corroborated the substantial vulnerability of the Asian SLE population to renal affliction. Add-on low-dose IV belimumab (1 mg/kg) and SC belimumab appeared protective against renal flares in nephritis-naïve patients with SLE. The approved IV dose (10 mg/kg) yielded no clear protection.
|
|
